Drug Profile
Research programme: immunocytokine anti-cancer therapeutics - Provenance
Alternative Names: Anti-CSPG4-IL2; Anti-EpCAM-IL2Latest Information Update: 28 Oct 2021
Price :
$50
*
At a glance
- Originator Provenance Biopharmaceuticals
- Class Antibodies; Antineoplastics; Cytokines; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Malignant melanoma; Neuroblastoma; Prostate cancer
Most Recent Events
- 28 Oct 2021 No recent reports of development identified for preclinical development in Neuroblastoma in USA (Parenteral)
- 28 Jun 2018 No recent reports of development identified for preclinical development in Malignant-melanoma in USA (Parenteral)
- 28 Jun 2018 No recent reports of development identified for preclinical development in Prostate-cancer in USA (Parenteral)